Drug Trial Radar · NCT07372287
A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma
Last checked: Nov 19, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
230
Planned (sponsor's estimate)
Start
Jan 23, 2026
Primary completion
Dec 31, 2028
Study completion Mar 31, 2029
Sponsor
- Lead sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to severe asthma. The study consists of three periods, including an up to 4-week screening period, a 52-week double-blind randomized treatment period, and a 12-week safety follow-up period.
Conditions
- Moderate to Severe Asthma
Interventions
CM326Drug
subcutaneous injection
PlaceboOther
subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized rate of severe asthma exacerbations at Week 52Time frame: week 52
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ruijin Hospital, Shanghai Jiao tong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.